Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term interleukin-2. Found 11 abstracts

Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S. Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. PharmacoEconomics. 2010 Jan;28(7):577-84.   PMCID: not NIH funded
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2006 Jan;24(1):16-24.
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Jun;295(21):2516-24.
Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, Torosian MH, Duffy K, Sickles C, Stadtmauer EA, Santoli D. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clinical Cancer Research. 2000 May;6(5):1744-54.
Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH, Schiller JH. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep;25(3):199-206.
Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon. Medical Oncology. 1998 Sep;15(3):191-8.
Young RC. Metastatic renal-cell carcinoma: What causes occasional dramatic regressions?. New England Journal of Medicine. 1998 Apr 30;338(18):1305-6.
Krigel RL, Padavicshaller K, Toomey C, Comis RL, Weiner LM. Phase-I Study of Sequentially Administered Recombinant Tumor- Necrosis-Factor and Recombinant Interleukin-2. Journal of Immunotherapy. 1995 Apr;17(3):161-70.
Barker CS, Bear SE, Keler T, Copeland NG, Gilbert DJ, Jenkins NA, Yeung RS, Tsichlis PN. Activation of the Prolactin Receptor Gene by Promoter Insertion in a Moloney Murine Leukemia Virus-Induced Rat Thymoma. Journal of Virology. 1992 Nov;66(11):6763-8.
Konrad MW, Dewitt SK, Bradley EC, Goodman G, Groves EC, Hersh EM, Krigel RL, Rudolph A. Interferon-Gamma Induced by Administration of Recombinant Interleukin-2 to Patients with Cancer - Kinetics, Dose Dependence, and Correlation with Physiological and Therapeutic Response. Journal of Immunotherapy. 1992 Jul;12(1):55-63.
Yeung RS, Vollmer C, Taylor DD, Palazzo J, Weese JL. Intratumoral Ril2-Based Immunotherapy in B16 Melanoma. Journal of Surgical Research. 1992 Aug;53(2):203-10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term interleukin-2

Last updated on Thursday, April 02, 2020